Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source […]
MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I Clinical Trial for the Treatment for Pancreatic Cancer
MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug development company, announces that it has received notice from the U.S. Food […]
Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. […]
Jakafi Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation
In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that […]
Radioimmunotherapy and Gemcitabine Combination Shows Extended Survival Times for Metastatic Pancreatic Ductal Cancer Patients
In a recent study presented at the American Association for Cancer Research conference on Pancreatic Cancer: Innovation in Research and […]
The US Food and Drug Administration has approved the targeted drug Sutent® (sunitinib) for the treatment pancreatic neuroendocrine tumors (PNET). […]
The US Food and Drug Administration has approved Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors (PNET). Pancreatic […]
An investigational type of immune therapy that attacks the tissue around a tumor has shown promise in a small study […]
Among patients with advanced pancreatic cancer, treatment with a combination of Gemzar® (gemcitabine) and the investigational drug axitinib did not […]
A large randomized study demonstrated no significant improvement in survival with Gemzar® (gemcitabine) versus 5-fluorouracil (5-FU) for the adjuvant (post-surgery) […]
A novel chemotherapy regimen followed by radiation appears to be safe and effective for patients with locally advanced pancreatic cancer, […]
As the month of November brings pancreatic cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated pancreatic cancer information throughout the year.
Among patients with inoperable pancreatic cancer, Gemzar® (gemcitabine)-based chemotherapy results in longer survival and better quality of life than an alternative treatment regimen consisting of enzyme therapy, nutritional supplements, detoxification, and an organic diet. These results were published in the Journal of Clinical Oncology.
The quality of care for pancreatic cancer varies considerably among hospitals in the United States, according to the results of a study published in the Journal of the National Cancer Institute.
Neoadjuvant Radiation Improves Survival in Pancreatic Cancer Preoperative radiation nearly doubles the survival rate for patients with operable pancreatic cancer, […]
According to the results of a Phase II clinical trial, the addition of the investigational drug EndoTAG™-1 to chemotherapy with […]
Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers Researchers recommend that at least 15 lymph […]
Gemzar® Improves Survival with Early Pancreatic Cancer Adjuvant (post-surgery) chemotherapy with Gemzar® (gemcitabine) significantly improves disease-free and overall survival among […]